Oregovomab is under clinical development by OncoQuest and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase III drugs for Endometrial Cancer have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Oregovomab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oregovomab overview

Oregovomab is under development for the treatment of ovarian cancer, pancreatic ductal adenocarcinoma, fallopian tube cancer, peritoneal cancer, serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma and malignant Brenner's Tumor. Oregovomab is a murine monoclonal antibody. The drug candidate is administered through the intravenous route. It targets the circulating tumor-associated antigen CA125 (cancer antigen 125).

OncoQuest overview

OncoQuest., is a developer of immunotherapeutic products for the treatment of cancer. The company is headquartered in Canada.

For a complete picture of Oregovomab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.